Achieve Life Sciences (ACHV) Research & Development (2010 - 2026)

Achieve Life Sciences (ACHV) has 17 years of Research & Development data on file, last reported at $3.0 million in Q1 2026.

• Quarterly Research & Development fell 58.08% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.8 million (down 30.51% YoY) and the FY2025 annual result came in at $23.0 million, up 0.64% from the prior year.
• Research & Development eased to $3.0 million in Q1 2026, from $3.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $9.9 million in Q3 2022 to a low of $2.1 million in Q4 2023.
• A 5-year average of $5.6 million and a median of $5.3 million in 2025 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development tumbled 75.46% — and 2024, when it surged 245.13%.
• Tracing ACHV's Research & Development over 5 years: stood at $8.6 million in 2022, then plunged by 75.46% to $2.1 million in 2023, then surged by 245.13% to $7.3 million in 2024, then slumped by 47.37% to $3.8 million in 2025, then dropped by 22.53% to $3.0 million in 2026.
• The last three Research & Development figures came in at $3.0 million (Q1 2026), $3.8 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.